Feed / MLTX

MoonLake Immunotherapeutics

MLTX

Healthcare · 16.63 -18.5% today

Participation confirmed · construction unavailableMarket checked 20 Aug, 09:30 GMT-4

Jodie situation report

MoonLake Immunotherapeutics's move is being confirmed by its market group.

No new filing conclusion is available. 28 of 31 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 3 directly disclosed connections are confirming.

Company-18.5% todayVolume comparison unavailable
Market group28 of 31 activeBiotechnology Therapeutics · active
Disclosed network0 of 3 confirmingNo filing-linked name is confirming now
What would change this read
  • At least 21 of 31 members remain active in the next snapshot.
  • Capital-flow agreement rises above 55%.
  • A filing-linked outsider such as NRIX begins moving with the group.

Invalidation: The live read weakens if participation falls to 10 of 31 members or fewer.

Watch this read

Who this business touches

The relationships behind MLTX

Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.

Depends on

MRKMerck & Company, Inc.partnerFeb 25, 2026

We are currently a single asset company focused on the development of Sonelokimab ( “ SLK ”) , a novel tri-specific IL-17A and IL-17F inhibiting Nanobody, that we exclusively licensed from Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA,…

HTGCHercules Capital, Inc.lenderMay 11, 2026

Term Loan Facility In March 2025, we entered into a loan and security agreement (the “Original Loan and Security Agreement”) with Hercules Capital, Inc.

Depended on by

ORKAOruka Therapeutics, Inc.partnerMar 12, 2026

These include the biologic sonelokimab from MoonLake Immunotherapeutics targeting IL-17A/F, and several oral agents in development, including JNJ-2113 (icotrokinra) from Janssen targeting the IL-23 receptor, DC-853 (simepdekinra) from Eli Lilly targeting IL-1…

Filing peers

Companies whose filings use similar operating language.

Open the three relationships above to see Jodie’s filing proof. Pro unlocks 3 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →

What is moving around it

Live connections

MLTX is currently a Participant in the organic co-movement group Biotechnology Therapeutics. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.